March/April 2018
- Addyi Update
By Negar Esfandiari and Kara Cotto In 2015, Valeant, a pharmaceutical giant known for price gouging and shady business practices paid $1 billion in cash for a flawed sexual enhancement drug marketed to women with so-called “acquired generalized hypoactive sexual desire disorder.” The drug, flibanserin, is sold under the name “Addyi,” and is described as the female version of Viagra. Despite the huge amounts of money involved, the drug’s a bust. It’s crucial for women to understand the small pink pill’s dangerous ...
- Addyi UpdateBy Negar Esfandiari and Kara Cotto In 2015, Valeant, a pharmaceutical giant known for price gouging and shady business practices paid $1 billion in cash for a flawed sexual enhancement drug marketed to women with so-called “acquired generalized hypoactive sexual desire disorder.” The drug, flibanserin, is sold under the name “Addyi,” and is described as the female version of Viagra. Despite the huge amounts of money involved, the drug’s a bust. It’s crucial for women to understand the small pink pill’s dangerous ...